Previous 10 | Next 10 |
digicomphoto/iStock via Getty Images Synaptogenyx (SNPX), which has Bryostatin-1 in phase 2b for Alzheimer's disease, is up 26% in afternoon trading. After the closing bell yesterday, a piece from Seeking Alpha contributor DeepValuePlay called the company "the next big thing in Alzheimer's." ...
Gainers: Midatech Pharma (MTP) +33%.Cellect Biotechnology (APOP) +31%.iSun (ISUN) +23%.AGM Group (AGMH) +23%.Synaptogenix (SNPX) +21%9F (JFU) +18%.Capricor Therapeutics (CAPR) +15%.Clearside Biomedical (CLSD) +14%.Rezolute (RZLT) +14%.China Xiangtai Food (PLIN) +13%.Losers: ...
Gainers: Midatech Pharma (MTP) +37%, Cellect Biotechnology (APOP) +30%, Synaptogenix (SNPX) +24%, Clearside Biomedical (CLSD) +16%, Tiziana Life Sciences (TLSA) +16%.Losers: CureVac (CVAC) -44%, Novan (NOVN) -19%, Prothena (PRTA) -14...
Midatech Pharma (MTP) +50% on the successful encapsulation of a biologic using Q-Sphera technology.Cellect Biotechnology (APOP) +40%.Clearside Biomedical (CLSD) +23% after filing registration statement for Quoin Pharma merger.Nano-X Imaging (NNOX) +16% after submits 510(k) appl...
The company's Bryostatin drug is likely to read out positive data in current phase 2, despite its checkered past. Its current market cap is extremely low compared to other companies in this space - suggesting significant upside. A Nasdaq up-listing provides a catalyst as volume is...
Synaptogenix Announces $12.5 Million Private Placement PR Newswire NEW YORK , June 14, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today an...
Synaptogenix ([[SNPX]] +9.0%) announces an update on its ongoing National Institutes of Health ("NIH") sponsored Phase 2b clinical trial of Bryostatin-1 in patients suffering from moderately severe Alzheimer's disease ("AD").The company has now dosed 58 of its target 100 patients, and se...
Synaptogenix Announces Phase 2b NIH Sponsored Alzheimer's Disease Trial Update - Data Safety Monitoring Board confirms Bryostatin-1 Safety PR Newswire NEW YORK , June 9, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmace...
Synaptogenix (SNPX), an ultramicrocap with a market cap of just $24.4M, is down 5.6% following the approval of Biogen's (BIIB) Aduhelm (aducanumab).Shares earlier in the day were up by more than 10%.The company's lead compound, bryostatin, is in phase 2 for moderately severe to seve...
Synaptogenix Responds to FDA Approval of Aducanumab PR Newswire NEW YORK , June 7, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today issued a st...
News, Short Squeeze, Breakout and More Instantly...
Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis PR Newswire Collaborative study will evaluate drug's potential to improve synaptic health and cognitive function in MS patients NEW YORK , ...
Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery PR Newswire Proposed Schedule III drug classification expected to de-risk Cannasoul's cannabis research and potential regulatory pathways ...